Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. 2seventy bio's Revenue for the
three
months ended in Mar. 2025 was MXN469.3 Mil. 2seventy bio's average Accounts Receivable for the
three
months ended in Mar. 2025 was MXN325.9 Mil.
Hence, 2seventy bio's Receivables Turnover for the
three
months ended in Mar. 2025 was 1.44.
2seventy bio (MEX:TSVT) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
2seventy bio Receivables Turnover Related Terms
2seventy bio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for 2seventy bio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TSVT vs ALMS, TERN, CRVS: Receivables Turnover Comparison
For the Biotechnology subindustry, 2seventy bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2seventy bio Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2seventy bio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where 2seventy bio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2seventy bio (MEX:TSVT) has a Receivables Turnover of 1.44 as of Mar. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 2seventy bio and its competitors.
Is 2seventy bio's Receivables Turnover too high?
2seventy bio's current Receivables Turnover is 1.44. The Biotechnology industry median Receivables Turnover is 5.28. 2seventy bio's value of 1.44 is 72.7% below this industry median. Overall, 2seventy bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does 2seventy bio's Receivables Turnover compare to ALMS and TERN?
2seventy bio's Receivables Turnover of 1.44 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. 2seventy bio's value of 1.44 is 72.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 2seventy bio's current Receivables Turnover of 1.44 is 72.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 2seventy bio and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 2seventy bio's current Receivables Turnover is 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2seventy bio stock overvalued right now?
2seventy bio (MEX:TSVT) has a current Receivables Turnover of 1.44. The current Receivables Turnover is 1.44 and 72.7% below the Biotechnology industry median of 5.28. 2seventy bio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For 2seventy bio (MEX:TSVT), the current Receivables Turnover is 1.44 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
9GF Score
Get the complete analysis for MEX:TSVT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TSVT has been successfully added to your 
